• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Hero Background

    Atrial Fibrillation Systems Companies

    ID: MRFR/HC/5058-HCR
    90 Pages
    Rahul Gotadki
    October 2025

    Atrial fibrillation (AFib) is a common heart rhythm disorder characterized by irregular and often rapid heartbeats. Treatment and management of AFib involve various approaches, including medications, lifestyle modifications, and medical devices.

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Atrial Fibrillation Market Research Report — Global Forecast till 2035 Infographic
    Summary Table of Contents Segmentation Download PDF

    Top Industry Leaders in the Atrial Fibrillation Systems Market

    Atrial Fibrillation Key CompaniesLatest Atrial Fibrillation Companies Update



    • November 2023: In patients with atrial fibrillation with rapid ventricular rate (AFib-RVR), etripamil nasal spray demonstrated rapid and statistically superior ventricular rate reduction and improved symptom relief compared to placebo, according to positive Phase 2 data released today by Milestone Pharmaceuticals Inc. The safety and tolerability findings from the safety population consisting of 56 patients are comparable to those reported in Milestone's Phase 3 paroxysmal supraventricular tachycardia (PSVT) program, which is significantly larger in scale. Concurrently with their Featured Science presentation at the American Heart Association (AHA) Scientific Sessions 2023 and publication in Circulation: Arrhythmia and Electrophysiology, the findings were unveiled. Further development of self-administered etripamil for the treatment of AFib-RVR is supported by these findings.



    • During a Late-Breaking session of the American Heart Association (AHA) meeting in November 2023, Anthos Therapeutics, Inc., a clinical stage company established by Blackstone Life Sciences and focused on developing novel therapies for cardiovascular diseases, disclosed that abelacimab exhibited a substantially reduced occurrence of bleeding events across all primary and secondary endpoints when compared to a direct-oral anticoagulant (DOAC), which is the standard of care. An extension study has been initiated by Anthos Therapeutics to facilitate the transition of patients from rivaroxaban to abelacimab in order to capitalize on the enhanced hemorrhage profile. Anticoagulation therapy aims to heal or prevent thrombosis while minimizing hemostasis disruption. Despite the efficacy of presently accessible anticoagulants in preventing strokes among individuals with atrial fibrillation, the potential for hemorrhaging continues to be a concern.


    List of Atrial Fibrillation Key companies in the market


    • Johnson & Johnson Services Inc.




    • Abbott




    • Medtronic Plc




    • Boston Scientific Corporation




    • MicroPort Scientific Corporation




    • Biotronik SE & Co. KG




    • Koninklijke Philips N.V.




    • AtriCure Inc.




    • CardioFocus




    • Osypka AG